7 Best Medical Technology Stocks To Buy According To Analysts

3. LivaNova PLC (NASDAQ:LIVN)

Price Target Upside: 41.53%

LivaNova PLC (NASDAQ:LIVN) is a global medical technology company specializing in innovative devices for cardiovascular and neuromodulation therapies. Its product portfolio includes heart-lung machines, oxygenators, and neuromodulation devices, primarily sold to hospitals and healthcare providers. The company operates in two main segments: Cardiac Surgery, which offers a range of cardiopulmonary equipment, and Neuromodulation, focusing on devices like the VNS Therapy System for treating drug-resistant epilepsy and depression.

LivaNova PLC (NASDAQ:LIVN)’s Q4 2024 earnings showed solid growth despite some challenges. Overall revenue increased by 5%, with organic growth of 7% compared to Q4 2023. For the full year, organic revenue grew by 11%, marking two consecutive years of strong growth. The Cardiopulmonary segment led the way with an 11% increase in Q4 revenue, while revenue from epilepsy treatments in Europe and international markets declined by 9%.

LivaNova PLC (NASDAQ:LIVN)’s profitability improved, with an adjusted gross margin of 69% in Q4, up from 68% last year, and operating income rising to $56 million. However, adjusted diluted earnings per share dropped to $0.81 due to a higher tax rate. The corporation ended the year with a cash balance of $429 million, up significantly from $267 million at the end of 2023. Adjusted free cash flow also grew by 70% to $163 million.

As one of the best medical technology stocks, LivaNova PLC (NASDAQ:LIVN) is well-positioned for growth, with revenue growth expected to be between 5% and 6% in 2025. They also anticipate organic growth of 6% to 7%, adjusted EPS of $3.65 to $3.75, and adjusted free cash flow of $135 million to $155 million.